Trial results

A Neuropsychobiological Approach to Optimize Patient Selection for GLP-1-based Pharmacotherapy for Weight Management Across the Binge Eating Spectrum

NCT07870538 on ClinicalTrials.gov · last registry update 2026-10-13

Recruiting now, toward 96 participants. Due to report December 2028, alongside 27 other tracked readouts that quarter. Primary outcome, as filed: Change in Body Mass Index (BMI) after semaglutide treatment. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 1 time since then.

Status

RECRUITING

Phase

P4

Drug

semaglutide

Ozempic, Rybelsus, Wegovy

Sponsor

Universitaire Ziekenhuizen KU Leuven

Sponsor type

Other

Enrollment

96

Started

2026-08-26

Primary completion

2028-12 estimated

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

Change in Body Mass Index (BMI) after semaglutide treatment

Conditions studied

Obesity & Overweight

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.